Search Results - "De La Torre, Inmaculada"

Neutralizing monoclonal antibodies for treatment of COVID-19 by Taylor, Peter C., Adams, Andrew C., Hufford, Matthew M., de la Torre, Inmaculada, Winthrop, Kevin, Gottlieb, Robert L.

“…Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under…”
Get full text

Response to rituximab: has the original hypothesis been confirmed? by Cambridge, Geraldine, Torre, Inmaculada De La

“…Before the use of rituximab, the strongest accepted evidence for an association between B-cells and rheumatoid arthritis (RA) was that clinical disease was…”
Get more information

Quality of life in patients with breakthrough cancer pain in radiation oncology departments in Spain: the CAVIDIOR study by Hernanz de Lucas, Raúl, Nuñez Fernández, Míriam, Gómez-Caamaño, Antonio, Morera López, Rosa, Fortes de la Torre, Inmaculada, de la Torre Tomás, Alejandro, Muñoz-Garzón, Víctor, López Bermudo, Cristina, Mañas Rueda, Ana

“…The CAVIDIOR study evaluated quality of life (QoL) in patients with breakthrough cancer pain receiving palliative radiation therapy in radiation oncology…”
Get full text

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) by Morand, Eric F, Vital, Edward M, Petri, Michelle, van Vollenhoven, Ronald, Wallace, Daniel J, Mosca, Marta, Furie, Richard A, Silk, Maria E, Dickson, Christina L, Meszaros, Gabriella, Jia, Bochao, Crowe, Brenda, de la Torre, Inmaculada, Dörner, Thomas

“…Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata…”
Get full text

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review by Emery, Paul, Durez, Patrick, Hueber, Axel J, de la Torre, Inmaculada, Larsson, Esbjörn, Holzkämper, Thorsten, Tanaka, Yoshiya

“…Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid…”
Get full text

Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN by López-Romero, Pedro, Martinez-Gamboa, Lorena, Bang, Holger, de la Torre, Inmaculada, Holzkämper, Thorsten, Feist, Eugen

“…Background The development of autoantibodies in patients with rheumatoid arthritis (RA) has potential as a marker of treatment response. This analysis assessed…”
Get full text

Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry by Ten Klooster, Peter M, Versteeg, Letty G A, Oude Voshaar, Martijn A H, de la Torre, Inmaculada, De Leonardis, Francesco, Fakhouri, Walid, Zaremba-Pechmann, Liliana, van de Laar, Mart

“…The aim of this retrospective study was to examine the longitudinal association between disease activity and radiographic damage in a cohort of patients with…”
Get full text

Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52 by Behrens, Frank, Leage, Soyi Liu, Sapin, Christophe, Baou, Celine El, De La Torre, Inmaculada, Meszaros, Gabriella, Schett, Georg, Combe, Bernard, van den Bosch, Filip, Gossec, Laure

“…Introduction Improvements in both musculoskeletal and non-musculoskeletal manifestations are important treatment goals in psoriatic arthritis (PsA). Objective…”
Get full text

Correction to: Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52 by Behrens, Frank, Leage, Soyi Liu, Sapin, Christophe, El Baou, Celine, De La Torre, Inmaculada, Meszaros, Gabriella, Schett, Georg, Combe, Bernard, van den Bosch, Filip, Gossec, Laure

Get full text

Macrophage uptake and accumulation of folates are polarization‐dependent in vitro and in vivo and are regulated by activin A by Samaniego, Rafael, Palacios, Blanca Soler, Domiguez‐Soto, Ángeles, Vidal, Carlos, Salas, Azucena, Matsuyama, Takami, Sánchez‐Torres, Carmen, Torre, Inmaculada, Miranda‐Carús, Maria Eugenia, Sánchez‐Mateos, Paloma, Puig‐Kröger, Amaya

“…Folate handling is dependent on the macrophage polarization state, where folate metabolism could provide useful diagnostic or therapeutic markers for…”
Get full text

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis by Alten, Rieke, Burmester, Gerd R., Matucci-Cerinic, Marco, Salmon, Jean-Hugues, Lopez-Romero, Pedro, Fakhouri, Walid, de la Torre, Inmaculada, Zaremba-Pechmann, Liliana, Holzkämper, Thorsten, Fautrel, Bruno

“…Introduction RA-BE-REAL has the overall aim of defining a profile of patients with rheumatoid arthritis (RA) starting baricitinib or any other targeted…”
Get full text

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study by Ortea, Ignacio, Roschitzki, Bernd, López-Rodríguez, Rosario, Tomero, Eva G, Ovalles, Juan G, López-Longo, Javier, de la Torre, Inmaculada, González-Alvaro, Isidoro, Gómez-Reino, Juan J, González, Antonio

“…Response to treatment of rheumatoid arthritis shows large inter-individual variability. This heterogeneity is observed with all the anti-rheumatic drugs,…”
Get full text

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis by Morand, Eric, Smolen, Josef S, Petri, Michelle, Tanaka, Yoshiya, Silk, Maria, Dickson, Christina, Meszaros, Gabriella, de la Torre, Inmaculada, Issa, Maher, Zhang, Hong, Dörner, Thomas

“…ObjectivesTo assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable…”
Get full text

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib by Kay, Jonathan, Harigai, Masayoshi, Rancourt, Josh, Dickson, Christina, Melby, Thomas, Issa, Maher, de la Torre, Inmaculada, Isaka, Yoshitaka, Cardoso, Anabela, Saifan, Chadi, Keystone, Edward C, van Vollenhoven, Ronald F, Giles, Jon T, Huizinga, Tom WJ, Kremer, Joel M

“…ObjectiveTo characterise changes in selected haematological parameters following once-daily oral baricitinib dosing.MethodsData were pooled from eight…”
Get full text

Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study by Kristensen, Lars Erik, Ng, Khai Jing, Ngantcha, Marcus, Morel, Jacques, Lubrano, Ennio, Tillett, William, Alten, Rieke, Chandran, Vinod, Martinez Ferrer, Àngels, Zhu, Baojin, Kennedy, Dominika, Holzkämper, Thorsten, Gullick, Nicola, Kronbergs, Andris, Fakhouri, Walid, de la Torre, Inmaculada, McGonagle, Dennis G

“…BackgroundThe psoriatic arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT) assesses effectiveness and persistence of real-world PsA…”
Get full text

Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: An exploratory analysis by Ortea, Ignacio, Roschitzki, Bernd, Ovalles, Juan Gabriel, Longo, Javier López, de la Torre, Inmaculada, González, Isidoro, Gómez-Reino, Juan J., González, Antonio

“…Biologics such as TNF antagonists are a new class of drugs that have greatly improved Rheumatoid Arthritis (RA) treatment. However, for unknown reasons,…”
Get full text

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate by Fakhouri, Walid, Wang, Xiaofei, de La Torre, Inmaculada, Nicolay, Claudia

“…This article compares the effectiveness of baricitinib (BARI) 4 mg (oral, Janus kinase [JAK] 1/2 inhibitor) versus other targeted synthetic/biologic…”
Get full text

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis by Van De Laar, Celine J, Oude Voshaar, Martijn A H, Fakhouri, Walid K H, Zaremba-Pechmann, Liliana, De Leonardis, Francesco, De La Torre, Inmaculada, Van De Laar, Mart A F J

“…Baricitinib is a janus kinase (JAK1/JAK2) inhibitor developed for the treatment of patients suffering from rheumatoid arthritis (RA). Treating RA to the target…”
Get full text

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions by Sacristán, José A., Díaz, Silvia, de la Torre, Inmaculada, Inciarte-Mundo, José, Balsa, Alejandro

“…Treat-to-target (T2T) and dose tapering after obtaining the therapeutic objective (called “treat-to-budget”-T2B-in this Commentary) are the two most commonly…”
Get full text

Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanercept by Valor, Lara, Monteagudo, Indalecio, de la Torre, Inmaculada, Fernández, Carlos González, Montoro, María, Longo, Javier López, Carreño, Luis

“…Abstract Cutaneous polyarteritis nodosa (CPAN) is a form of necrotizing vasculitis of small and medium-sized arteries. It is limited to the skin and has a…”
Get full text